LWAM
VRTX icon

Legacy Wealth Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Wealth Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$743K Buy
1,496
+1
+0.1% +$443 0.16% 194
2026
Q1 		$668K Buy
1,495
+12
+0.8% +$5.6K 0.16% 212
2025
Q4 		$672K Buy
1,483
+41
+3% +$17.7K 0.17% 200
2025
Q3 		$565K Buy
1,442
+26
+2% +$10.9K 0.14% 236
2025
Q2 		$630K Sell
1,416
-13
-0.9% -$5.99K 0.16% 202
2025
Q1 		$693K Sell
1,429
-22
-2% -$10.3K 0.19% 164
2024
Q4 		$584K Sell
1,451
-7
-0.5% -$3.25K 0.16% 206
2024
Q3 		$678K Buy
1,458
+12
+0.8% +$5.76K 0.18% 181
2024
Q2 		$678K Sell
1,446
-2,938
-67% -$1.28M 0.19% 154
2024
Q1 		$1.83M Sell
4,384
-8
-0.2% -$3.38K 0.51% 49
2023
Q4 		$1.79M Sell
4,392
-12
-0.3% -$4.43K 0.59% 45
2023
Q3 		$1.53M Buy
4,404
+17
+0.4% +$5.95K 0.56% 48
2023
Q2 		$1.54M Buy
4,387
+1,164
+36% +$392K 0.54% 45
2023
Q1 		$1.02M Buy
3,223
+8
+0.2% +$2.4K 0.37% 76
2022
Q4 		$928K Buy
3,215
+6
+0.2% +$1.83K 0.35% 85
2022
Q3 		$929K Buy
+3,209
New +$923K 0.41% 75

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Legacy Wealth Asset Management's VRTX Position: Q2 2026 in Review

Legacy Wealth Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.07% in Q2 2026, buying an estimated $443 and bringing the position to 1,496 shares worth $743K. The position accounts for 0.16% of the portfolio, ranked #194.

Legacy Wealth Asset Management first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.83M in Q1 2024. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Legacy Wealth Asset Management held 1,496 shares of Vertex Pharmaceuticals worth $743K as of Q2 2026.
  • Legacy Wealth Asset Management bought 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
  • Vertex Pharmaceuticals made up 0.16% of Legacy Wealth Asset Management's portfolio in Q2 2026, its #194 holding.
  • Legacy Wealth Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Legacy Wealth Asset Management's Vertex Pharmaceuticals position peaked at $1.83M in Q1 2024.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Legacy Wealth Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.